Core Viewpoint - The company has received the production registration approval for Trospium Chloride Extended-Release Capsules (4mg) from the National Medical Products Administration of China, marking it as the third domestic company to obtain this approval [1] Group 1: Company Developments - The approval is classified as a Class 4 chemical drug and is considered equivalent to passing the consistency evaluation [1] - Trospium Chloride Extended-Release Capsules are primarily used for the treatment of overactive bladder syndrome [1]

本公告為本公司自願發佈，目的是使股東及潛在投資者瞭解本集團最新業務發展情況。 承董事局命 執行董事兼公司秘書 香港，二零二五年十一月二十八日 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不會就因本公告全部或任何部份內容而產生 或因倚賴該等內容而引致之任何損失承擔任何責任。 自願公告 產品開發的最新進展 石四藥集團有限公司（「本公司」，連同其附屬公司，「本集團」）董事局（「董事局」）欣然公告， 本集團已取得中國國家藥品監督管理局有關酒石酸托特羅定緩釋膠囊(4mg)的藥品生產註冊批 件，屬於化學藥品第4類，視同通過一致性評價，是國內企業第三家獲批。酒石酸托特羅定緩釋 膠囊主要用於治療膀胱過度活動症。 於本公告日期，董事局成員包括執行董事曲繼廣先生、蘇學軍先生、孟國先生、周興揚先生及 曲婉蓉女士，非執行董事劉文軍先生，以及獨立非執行董事王亦兵先生、周國偉先生及姜廣策 先生。 周興揚 ...

Core Viewpoint - The company Shijiazhuang Pharmaceutical Group has received approval from the National Medical Products Administration of China for its Vitamin A Palmitate to be registered as an active pharmaceutical ingredient for use in marketed formulations [1] Group 1 - The approved Vitamin A Palmitate is primarily used in fat-soluble vitamin injection solutions to supplement vitamins [1]

Core Viewpoint - The company Shijiazhuang Pharmaceutical Group has received approval from the National Medical Products Administration of China for its Vitamin A Palmitate to be used as an active pharmaceutical ingredient in marketed formulations [1] Group 1 - The approved Vitamin A Palmitate is primarily used in fat-soluble vitamin injection solutions to supplement vitamins [1]

Core Viewpoint - The company Shihua Pharmaceutical Group has received approval from the National Medical Products Administration of China for its Vitamin A Palmitate to be used as an active pharmaceutical ingredient in marketed formulations [1] Group 1 - The Vitamin A Palmitate is primarily used in fat-soluble vitamin injections to supplement vitamins [1]

Core Viewpoint - The company Shijiazhuang Pharmaceutical Group (stock code: 02005) has received approval from the National Medical Products Administration of China for its Vitamin A Palmitate to be registered as an active pharmaceutical ingredient for use in marketed formulations [1] Group 1 - The approved Vitamin A Palmitate is primarily used in lipid-soluble vitamin injections to supplement vitamins [1]

石四藥集團有限公司（「本公司」，連同其附屬公司，「本集團」）董事局（「董事局」）欣然公告， 本集團的維生素 A 棕櫚酸酯已獲中國國家藥品監督管理局批准登記成為在上市製劑使用的原 料藥。維生素 A 棕櫚酸酯主要用於脂溶性維生素注射液，補充維生素。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不會就因本公告全部或任何部份內容而產生 或因倚賴該等內容而引致之任何損失承擔任何責任。 自願公告 產品開發的最新進展 香港，二零二五年十一月二十七日 於本公告日期，董事局成員包括執行董事曲繼廣先生、蘇學軍先生、孟國先生、周興揚先生及 曲婉蓉女士，非執行董事劉文軍先生，以及獨立非執行董事王亦兵先生、周國偉先生及姜廣策 先生。 本公告為本公司自願發佈，目的是使股東及潛在投資者瞭解本集團最新業務發展情況。 承董事局命 執行董事兼公司秘書 周興揚 ...

备注：持股数变动有可能因供股、合股、拆股等情况引起，请注意对照实际情况进行辨别。 | 股票名称 | 机构名称 | 性质 | 变动前持股 | 变动后持股 | 持股比 | | --- | --- | --- | --- | --- | --- | | 石四药集团 | 曲继广 | 好仓 | 12.24 亿股 | 12.26 亿股 | 41.54%(最新) | | (02005) | | | | | 41.46%(前次) | | 石四药集团 | China Pharmaceutical | 好仓 | 8.86 亿股 | 8.89 亿股 | 30.11%(最新) | | (02005) | Company Limited | | | | 30.03%(前次) | 智通财经APP获悉，石四药集团(02005)于2025年11月27日进行了最新股东权益披露。 ...

Core Viewpoint - 石四药集团 has received production registration approval from the National Medical Products Administration of China for Indobufene Tablets (0.2g), which is classified as a Class 3 chemical drug and is considered to have passed the consistency evaluation [1] Group 1: Company Developments - 石四药集团's stock rose nearly 3%, currently up 2.68% at HKD 3.06, with a trading volume of HKD 16.01 million [1] - The Indobufene Tablets are primarily used for treating ischemic cardiovascular diseases caused by arteriosclerosis, ischemic cerebrovascular diseases, and venous thrombosis, and can also be used to prevent thrombosis during hemodialysis [1] Group 2: Market Insights - Indobufene Tablets, developed by an Italian company, have become a substitute for aspirin for patients who are intolerant to it [1] - According to the MoShang Pharmaceutical Database, the total hospital sales of Indobufene Tablets exceeded 1 billion in 2022, showing a year-on-year growth over the past three years [1] - Sales are projected to exceed 1.9 billion in 2024, with a year-on-year increase of 37.47%, and over 1.1 billion in the first half of 2025, with a year-on-year increase of 28.07% [1] - The high sales figures have attracted attention from numerous pharmaceutical companies, intensifying market competition [1]

Core Viewpoint - Stone Four Pharmaceutical Group has seen a nearly 3% increase in stock price following the announcement of obtaining production registration for Indobufene tablets from the National Medical Products Administration of China, indicating a significant development in their product pipeline [1] Company Summary - Stone Four Pharmaceutical Group's stock rose by 2.68% to HKD 3.06, with a trading volume of HKD 16.01 million [1] - The company has received approval for Indobufene tablets (0.2g), classified as a Class 3 chemical drug, which is considered equivalent to passing the consistency evaluation [1] Product Summary - Indobufene tablets are primarily used for treating ischemic cardiovascular diseases caused by arteriosclerosis, ischemic cerebrovascular diseases, and venous thrombosis, and can also prevent thrombosis during hemodialysis [1] - Developed by an Italian company, Indobufene has become a substitute for aspirin in patients who are intolerant to it [1] Market Summary - According to the MoSheng Pharmaceutical Database, the total hospital sales of Indobufene tablets exceeded 1 billion in 2022, showing a year-on-year growth over the past three years [1] - Sales are projected to surpass 1.9 billion in 2024, reflecting a year-on-year increase of 37.47%, and exceed 1.1 billion in the first half of 2025, with a year-on-year growth of 28.07% [1] - The high sales figures have attracted attention from numerous pharmaceutical companies, intensifying market competition [1]